ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

ORIC Pharmaceuticals to participate in several investor conferences in September

SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in the first half of September:

• Citi’s 2023 18^th Annual BioPharma Conference – Participating in a targeted oncology panel on Wednesday, September 6, 2023, at 1:00 p.m. ET
  
  
• Wells Fargo 2023 Healthcare Conference – Participating in a fireside chat on Thursday, September 7, 2023, at 11:00 a.m. ET
  
  
• H.C. Wainwright 25^th Annual Global Investment Conference – Presenting company overview on Monday, September 11, 2023, at 12:30 p.m. ET
  
  
• Baird 2023 Global Healthcare Conference – Participating in a fireside chat on Tuesday, September 12, 2023, at 2:35 p.m. ET
  

Webcasts of the panel discussion and presentations will be available through the investor section of the company’s website at www.oricpharma.com. Replays of webcasts will be available for 90 days following the events.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com